Please use this identifier to cite or link to this item:
Title: The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody
Authors: Chan, Conrad E. Z.
Seah, Shirley G. K.
Chye, De Hoe
Massey, Shane
Torres, Maricela
Lim, Angeline P. C.
Wong, Steven K. K.
Neo, Jacklyn J. Y.
Wong, Pui San
Lim, Jie Hui
Loh, Gary S. L.
Wang, Dongling
Boyd-Kirkup, Jerome D.
Guan, Siyu
Thakkar, Dipti
Teo, Guo Hui 
Purushotorman, Kiren 
Hutchinson, Paul E. 
Young, Barnaby E.
Low, Jenny G. 
MacAry, Paul A. 
Hentze, Hannes
Prativadibhayankara, Venkateshan S.
Ethirajulu, Kantharaj
Comer, Jason E.
Tseng, Chien-Te K.
Barrett, Alan D. T.
Ingram, Piers J.
Brasel, Trevor
Hanson, Brendon John
Issue Date: 23-Jun-2021
Publisher: Public Library of Science
Citation: Chan, Conrad E. Z., Seah, Shirley G. K., Chye, De Hoe, Massey, Shane, Torres, Maricela, Lim, Angeline P. C., Wong, Steven K. K., Neo, Jacklyn J. Y., Wong, Pui San, Lim, Jie Hui, Loh, Gary S. L., Wang, Dongling, Boyd-Kirkup, Jerome D., Guan, Siyu, Thakkar, Dipti, Teo, Guo Hui, Purushotorman, Kiren, Hutchinson, Paul E., Young, Barnaby E., Low, Jenny G., MacAry, Paul A., Hentze, Hannes, Prativadibhayankara, Venkateshan S., Ethirajulu, Kantharaj, Comer, Jason E., Tseng, Chien-Te K., Barrett, Alan D. T., Ingram, Piers J., Brasel, Trevor, Hanson, Brendon John (2021-06-23). The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. PLoS ONE 16 (6-Jun) : e0253487. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Although SARS-CoV-2-neutralizing antibodies are promising therapeutics against COVID- 19, little is known about their mechanism(s) of action or effective dosing windows. We report the generation and development of SC31, a potent SARS-CoV-2 neutralizing antibody, isolated from a convalescent patient. Antibody-mediated neutralization occurs via an epitope within the receptor-binding domain of the SARS-CoV-2 Spike protein. SC31 exhibited potent anti-SARS-CoV-2 activities in multiple animal models. In SARS-CoV-2 infected K18-human ACE2 transgenic mice, treatment with SC31 greatly reduced viral loads and attenuated proinflammatory responses linked to the severity of COVID-19. Importantly, a comparison of the efficacies of SC31 and its Fc-null LALA variant revealed that the optimal therapeutic efficacy of SC31 requires Fc-mediated effector functions that promote IFN?-driven anti-viral immune responses, in addition to its neutralization ability. A dose-dependent efficacy of SC31 was observed down to 5mg/kg when administered before viral-induced lung inflammatory responses. In addition, antibody-dependent enhancement was not observed even when infected mice were treated with SC31 at sub-therapeutic doses. In SARS-CoV-2- infected hamsters, SC31 treatment significantly prevented weight loss, reduced viral loads, and attenuated the histopathology of the lungs. In rhesus macaques, the therapeutic potential of SC31 was evidenced through the reduction of viral loads in both upper and lower respiratory tracts to undetectable levels. Together, the results of our preclinical studies demonstrated the therapeutic efficacy of SC31 in three different models and its potential as a COVID-19 therapeutic candidate. © 2021 Chan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Source Title: PLoS ONE
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0253487
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0253487.pdf2.63 MBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons